10.00–18.00

Registration Open

Entrance Erasme

10.00–18.00

Speaker Presentation Check-In

Salon President

13.00–16.00

Pre-Conference Educational

Paediatric Course
Cost: €50 - (Places must be pre-booked)
Chairs: F Schaefer, Heidelberg, Germany; B Warady, Kansas City, USA

13.00–13.30 PD Prescription: Fill Volume, Dwell Time
M Fischbach, Strasbourg, France
How to prescribe a fill volume from babies to adolescents; which impact on tolerance and dialysis efficacy; the importance of the dwell time on ultrafiltration and purification

13.30–14.00 PD Prescription: The PDFs Choice
C Schmitt, Heidelberg, Germany
From composition to biocompatibility of the peritoneal dialysis fluids. Discuss the clinical place for the new PDFs

14.00–14.30 Assessment of the Peritoneal Membrane: Is the PET Enough?
B Warady, Kansas City, USA
How to test peritoneal membrane permeability; when and how to prescribe a PET; impact on prescription and outcome (hyperpermeability, hypopermeability: risks)  

14.30–15.00 Tea/Coffee    

15.00–15.30 Peritonitis: How to Manage it?
F Schaefer, Heidelberg, Germany
How to define a peritonitis; what to do in terms of first choice for antibiotic treatment; how to prescribe peritoneal dialysis over a peritonitis episode, how to prevent

15.30–16.00 The Peritoneal Catheter
J Terzic, and F Becmeur, Strasbourg, France
The catheter choice, the catheter placement, the catheter follow up, from babies to adolescents, a need for adequate management.

Kleber

13.00–16.00

Pre-Conference Educational Course II
Cost: €50 - (Places must be pre-booked)
Chairs: W Van Biesen, Gent, Belgium;  B Faller, Colmar, France  

13.00–13.20 Peritoneal Physiology and Anatomy
S Fan, London, UK
Overview of the anatomy of the peritoneal membrane, basic understanding of small solute transport and sodium sieving, 3 pore theory

13.20–13.40 Peritoneal Cell Populations and their Relevance to Clinical PD
G Roberts, Cardiff, UK
Overview of the resident cell populations in the peritoneal cavity and the peritoneal membrane, and how their function changes with PD duration and during infection.

13.40–14.00 Treatment Strategies for PD Related Peritonitis
R Krediet, Amsterdam, The Netherlands
Risk factors for peritonitis, the prevention of peritonitis, the need for epidemiologic studies, key issues when developing an empirical antibiotic therapy strategy.

14.00–14.20 Volume Management in PD
S Davies, Stoke on Trent, UK
Volume status in PD, importance of residual renal function, evaluation methods of volume status, how to achieve euvolemia.

14.20–14.50 Tea/Coffee

14.50–15.10 Optimal Clearance in PD
W Van Biesen, Gent, Belgium
Importance of small solute clearance, improving small solute clearance, avoiding high volume regimens, dwell time, dwell volumes, breakpoint analysis.

15.10–15.30 Enlarging the PD Population
J D Williams, Cardiff, UK
Strategies to enhance the numbers of incident patients starting on PD and strategies to improve technique success

15.30–15.50 Opportunities and Pitfalls of Assisted Care
C Verger, Pontoise, France
Different strategies to implement assisted care and different levels of assisted care

15.50-16.00 Discussion

Schuman

10.00-18.00

Registration Open
Speaker Presentation Check-In

Entrance Erasme
Salon President

16.30-18.00

Welcome & Opening Plenary

Chairs: J D Williams, Cardiff, UK; M Fischbach, Strasbourg, France

16.30-16.40 Welcome

16.40–17.10 Cultural Event:
- Ecole de Musique de Schiltigheim (Claude Siegwald)
- Harpist School (Marie Madelaine Sigward)
- Les Petits Chanteurs de Strasbourg (Philippe Utard)

17.10–18.00 The Evolving Landscape of European Renal Replacement Therapies: What We Can Learn From the ANZDATA
D Johnson, Brisbane, Australia

Erasme Hall

18.00-19.30

Industry Symposium I


Hyperphosphatemia; Early Management and Treatment Considerations to Improve Patient Outcomes
Chair: Prof. J Bommer, Medical Clinic, University of Heidelberg, Germany

Calcium Myths
Dr. C. Ferro, Queen Elizabeth Hospital, Birmingham, UK

Early Management of Hyperphosphatemia and its Treatment With a Novel Therapy
Prof. J Bommer, Medical Clinic, University of Heidelberg, Germany

Q&A Session

Erasme Hall

19.30–21.00

Opening of the Exhibition and 9th EuroPD Welcome Reception
Supported by

Exhibition Foyer

07.00–18.45
07.00–18.45
10.00–17.30

Registration and Posters Open
Speaker Presentation Check-In
Exhibition & Internet Cafe

Entrance Erasme
Salon President
Exhibition Foyer

Masterclasses: Session I
(by invitation only)

07.45–08.30 Theme A1: Peritoneal Dialysis Adequacy
O Heimburger, Stockholm, Sweden

07.45–08.30 Theme B1: Peritoneal Dialysis and Access
A Slingeneyer, Montpellier, France  

07.45–08.30 Theme C1: Assessment of Peritoneal
Transport Characteristics
S Davies, Stoke on Trent, UK; B Rippe, Lund, Sweden

Kleber

Rohan

Gutenberg

08.30–10.00

Symposium I

PD in the Diabetic Patient
Chairs: W Van Biesen, Gent, Belgium; B Issad, Paris, France

08.30-08.50 Adipocyte Metabolism in Chronic Renal Failure and Dialysis
L Ranganath, Liverpool, UK

08.50-09.10 Recent Advances in the Relationship Between Inflammation, Obesity and Insulin Resistance
JP Bastard, Paris, France
Type 2 diabetes is linked to obesity and insulin resistance. PD can also be linked to obesity and insulin resistance, due to the enhanced glucose uptake. How can our current understanding of the pathophysiology of type 2 diabetes help us to understand the eventual link between PD and diabetes? What is the role of the adipocyte in the chronic inflammation observed in PD patients? And what is the link between inflammation and insulin resistance? Can this be the explanation for the observed higher mortality in older female diabetic PD vs HD patients?

09.10-09.35 Treatment Regimens for Diabetes In 2009
M Giri, Ghent, Belgium
Optimal control of glucose is key to improve survival in diabetic patients. What are the current treatment strategies for diabetic patients (especially type 2) with chronic renal failure: new insulins, new oral drugs, the place of methformin, thiazolidines or glipinide, physical exercise, diet.

09.35-10.00 Metabolic and Symptom Control in Diabetic Patients on PD
O Heimburger, Stockholm, Sweden
What is the impact of PD on diabetes? How many PD patients develop diabetes? Evolution of glycemic control? PD practice and its impact on diabetes, e.g. use of hypertonic exchanges. Treatment of polyneuropathy? Impact of glucose on haemodynamic parameters? The diabetic foot in PD patients? Lipid profiles and treatment?

Erasme Hall

10.00-10.30

Tea/Coffee

Exhibition Foyer

10.30-12.00

Symposium IIa

Paediatric Experiences of Interest for Adult Care
Chairs: J Vandewalle, Gent, Belgium ; B Warady, Kansas City, USA

10.30-11.00 Improving PD for Children Worldwide. The Impact of the International Paediatric Peritoneal Dialysis Network
B Warady, Kansas City, USA

11.00-11.20 Gastrostomy in PD Patients: Risky?
A Edefonti, Milan, Italy

11.20-11.40 Dialysis for Acute Metabolic Diseases: Is there a Place for PD?
C Stefanidis, Athens, Greece

11.40-12.00 Impact of the PDFs on the Membrane Permeability
C Schmitt, Heidelberg, Germany

Salle Schuman

10.30-12.00

Symposium IIb

PD in the Elderly Patient:
Chairs: C Verger, Pontoise, France; E Brown, London, UK

10.30-10.55 Evaluation of Cognitive and Physical Function in the Elderly
N Van De Noorgate, Gent, Belgium
A correct estimation of the mental and cognitive function of elderly patients is crucial in the decision making process regarding dialysis: yes or no RRT, type of RRT, can the patient remain at home, or should he/she be transferred to a nursing home? How can we correctly evaluate the physical and mental function of our patients to support these decisions. What is their predictive/diagnostic value; Are there “objective” investigations (Scans, PET, MR,?) that can be of help.

10.55-11.15 Cognitive and Physical Function in the Elderly Dialysis Patient: Strategies for Improvement?
V Jassal, Toronto, Canada
How can we stimulate our patients to improve their cognitive skills and their physical powers? Physiotherapy? Electrostimulation? Dietary measures?

11.15-11.40 What are the Barriers to PD in the Elderly:
Outcomes of the BOLDE Study
E Brown, London, UK
Many consider older age and lower physical and mental condition a contra-indication for PD. Is this really the case, or can solutions be found to make PD a good and valuable alternative to HD?

11.40-12.00 Associations Between Comorbidities, Treatment Choice
and Outcome in The Elderly with End-Stage Renal Disease
T Lobbedez, Caen, France
Description of the results obtained in France.

Erasme Hall

12.00–14.00

Lunch/Posters/Exhibition
(Lunch can be taken into the auditorium for the Fresenius symposium)

Exhibition Foyer

12.15–13.45

Industry Symposium II 

Improving Outcomes with Modern Therapy Concepts
Chairs: Achim Jörres, Berlin, Germany; John D Williams, Cardiff, Wales

Biocompatible Low GDP - PD Solutions - A Treatment For All Patients?
M Feriani, Mestre, Italy

Peritoneal Dialysis In Children: How Adapted Fill Volume and Dwell Time Improve PD Efficiency
M Fischbach, Strasbourg, France

Volume Status In PD Patients: Facts And Fiction
W Van Biesen, Gent, Belgium

Erasme Hall

13.45-15.00

Poster Session I

ANIMOD - Posters: P1 – P5
P Ter Wee, The Netherlands; J Witowski, Poland; R Selgas, Spain

Cardiovascular - Posters : P6 – P15
J Heaf, Denmark; PY Durand, France,

Clinical PD - Posters: P16-P37
O Heimburger, Sweden; B Faller, France; J Chanliau, France;
B Bammens, Belgium

Paediatrics - Posters: P109, P143 - P145
A Edefonti, Italy; D Stefanidis, Greece

Other - Posters: P-124-P142
E Brown, UK; E Goffin, Belgium

Ground Floor

14.00-15.00

Mini Symposium I

The Place of PD in the Intensive Care Unit
Chairs: A Jorres, Berlin, Germany; M Tsimaratos, Marseille, France

PD is often not considered as a good alternative for other extracorporeal techniques in ICU patients with ARF.

14.00-14.30 PD for Paediatric Patients at ICU: Tips and Tricks
J Vandewalle, Gent, Belgium
In small children, PD is often used as an alternative for extracorporeal treatment. What are the key points to make it a successful treatment: access, solutions, ultrafiltration, clearance;  tolerance (IPP), exchange permeability,
its place in cases of HUS or post cardiac surgery will be discussed.

14.30-15.00 Is There still a Place for PD in Adults at ICU?
A Jorres, Berlin, Germany
Many consider PD as inadequate in the catabolic patients with ARF at ICU.
In contrast, PD has some advantages: haemodynamic stability, no requirement for anticoagulation, no changes in intracerebral pressure or perfusion.
What can be ideal indications for PD at ICU? What should be yhe key points
to make it a good and successful treatment? Access? Clearance? Ultrafiltration? Solutions?

Erasme Hall

14.00-15.00

Free Communications I

Clinical Session
 Chair: Wim Van Biesen, Gent, Belgium

14.00-14.12 O-1 Quality of Life in Older Peritoneal and Haemodialysis Patients: Results from the BOLDE Study
Lina Johansson, Nigel Beckett, Maria Da Silva-Gane, Ken Farrington, Hugh Gallagher, Mary Hickson, Tom Sensky, Edwina Brown

14.12-14.24 O-2 Engendering Hope in Patients Receiving Dialysis Treatment. Dialysis Patient’s Illustration of Hope, the Related Factors
and Helping Methods
Sinikka Kuohula

14.24-14.36 O-3 The Apd Treatment with a Cycler Personalised Breakpoint improves Peritoneal Dialytic Kt/V: A Pilot Study 
Roberto Dell’Aquila, Ivo Baragetti, Marco Pozzi, G. Berlingò, Elena Alberghini, Lucia Pisano, Andrea Galassi, Claudio Pozzi, Renzo Scanziani

15.36-15.48 O-4 The Patient Pathway - Improving the Patient’s Transition from CKD to Peritoneal Dialysis
Lesley Lappin, David Lewis, Annette Knaggs, Sarah Bridgford

15.48-15.00 O-5 Are Survival Curves in Peritoneal Dialysis False?
The Importance of Competing Risks in Survival Analysis
Jean Baptiste Beuscart, Dominique Pagniez, Eric Boulanger, Celia Lessore De Sainte Foy, Julia Salleron, Luc Frimat, Alain Duhamel

Schuman Room

15.00–17.00

Clinical Practice Session I

PD in the Frail Patient
Chairs: M Dratwa, Brussels, Belgium;  J Chanliau, Nancy, France

15.00-15.40 Mini-Debate: Offering Assisted PD to the Elderly is Mandatory to Expand Patient Numbers  

CON: P Ter Wee, Amsterdam, The Netherlands
PRO: J Heaf, Herlev, Denmark

Can the development and support of assisted PD result in an increase in prevalence of PD?  

15.40-16.05 Starting Patients Who are Referred Late on PD
T Lobbedez, Caen, France
The majority of patients referred late still end up on HD, and do not transfer back to PD. There are however some clear advantages to PD even in late referrals: no need for indwelling catheters, slow and gentle treatment preserving residual renal function and avoiding disequilibrium. Starting PD in late referrals requires some specific logistical approaches: access, starting regimens, education. Several reports are now available of successful programs with late referred patients on PD.

16.05-16.30 Treating PD Patients with Congestive Heart failure
A Vychytil, Wien, Austria
The prevalence of congestive heart failure is increasing rapidly, paradoxically because of the better care for cardiovascular care for patients. Most of these patients have also renal failure, and there is a constant search for equilibrium between good cardiac and renal function. Can PD be a solution for these patients? Which modalities/ regimens should be preferred? Pathophysiology: is it only fluid removal, or is there more going on?

16.30-17.00 Advance Care Planning and End of Life Care in ESRD
J Chambers, Bristol, UK
There is an increasing interest in “non dialysis” in frail patients, but in those who do not want to refrain completely, or for control of uremic symptoms, PD can be a suitable “palliative” RRT modality, where the “care” is the first issue of concern. Alternatively, in patients on long term RRT, there can come a moment when poor QoL becomes an issue. What should be done in these circumstances? Strategies of advanced care planning, therapy restrictions, caring not curing protocols.

Erasme Hall

17.15-18.45

Industry Symposium III

More choices for All
Chairman: M Fischbach, Strasbourg, France
Co-chairman: C Verger, Pontoise, France

Starting Dialysis for All
- Challenges of Unplanned Start, Consequences, Possible Approaches Including the Unplanned Start Programme
Ingrid Keur - The Netherlands

PD Prescribing for All
- Practical case based, key aspects of PD prescribing
(UF, Small solute, role of CAPD/APD)
Max Dratwa - Belgium

Benefits of Biocompatible Solutions for All
- Results of “late breaking” Study of Biocompatible Fluids From Korea
Dae Suk Han - Korea

Choice of Home Dialysis for All
- Home vs. Centre Choice, Integration of Modalities for
Improved Outcomes
Richard Fluck - United Kingdom

Erasme Hall

07.30-18.15
07.30-18.15
10.30-17.30

Registration and Posters Open
Speaker Presentation Check-In
Exhibition Open

Entrance Erasme
Salon President
E xhibition Foyer

Masterclasses A2/B2/C2

07.45-08.30 Theme A2: Volume Management on Peritoneal Dialysis 
J Heaf, Herlev, Denmark

07.45-08.30 Theme B2: PD in Specific Patient Groups
E Goffin, Brussels, Belgium

07.45-08.30 Theme C2: Growth Factors and Cytokines Relevant to PD
E Boulanger, Lille, France

Gutenberg

Kleber

Rohan

08.30-10.30

Symposium III

Infection and Peritoneal Dialysis
Chairs: J D Williams, Cardiff, UK; B Faller, Colmar, France

08.30-08.55 The Risk of Infection and its Complication are Worse in HD Than in PD
E Goffin, Brussels, Belgium
For most nephrologists, infection is “the” problem in PD. However, when looking to the alternative modality, HD, it is clear that the infection risk is higher there than in PD.

08.55-09.20 Mechanisms of Antibiotic Resistance: Lessons for the Nephrologist
D Vogelaers, Gent, Belgium
Guidelines for treatment of PD related peritonitis (and also for other infections in dialysed patients) cannot be made general in terms of type of antibiotic to choose, as local epidemiology and resistance patterns are key in the selection of type of antibiotic of choice. Knowledge and understanding of mechanisms of resistance of the different antibiotic classes is of importance in the selection process. What causes resistance? Which strategies to use to avoid resistance? What to do if we have MRSA or C. Difficile in PD patients?

09.20-09.40 More Lessons from the Paediatric Peritonitis Registry
F Schaefer, Heidelberg, Germany

09.40-10.05 Hepatitis Viruses and Peritoneal Dialysis
M Jadoul, Brussels, Belgium
Hepatitis (both B and C) remain problematic in some European countries, and remain a threat to the individual patient on RRT. The KDIGO guidelines do not give specific guidance on the relation PD-hep C. Can PD be of help? Should PD not be recommended in patients with hep C/B, or in centres where hep C/B is present? What to do with Hep C/B patients (waste handling, treatment)?

10.05-10.30 A Culture for PD
P Rutherford, Wallisellen, Switzerland
Culture negative peritonitis is an important risk factor for technique failure. What can we do to decrease the prevalence of “culture negative” peritonitis? What types of culture methods, or other diagnostic tools should we use to detect the responsible micro-organisms of peritonitis/tunnel infection?

Erasme Hall

10.30–11.00

Tea/Coffee

Exhibition Foyer

11.00–13.00

Clinical Practice Session II

Increasing Technique Success:
Preventing and Treating the Complications of PD
Chairs: E Goffin, Brussels, Belgium; O Heimburger, Stockholm, Sweden

11.00-11.20 Catheter Placement and Displacement
A Slingeneyer, Montpellier, France    
Access to the peritoneal cavity is key to good PD. Technical problems related to catheter dysfunction such as dislocation, or obstruction, decrease adequacy and QoL. This session deals with different methods for catheter placement and approach to, and correction of, dislocated catheters.

11.20-11.40 Sleep Disorders in CKD Stage 5
I Mucsi, Budapest, Hungary
Sleep apnoea is more prevalent than previously thought. PD might negatively impact on sleep apnoea: data, solutions.  

11.40-12.00 The Role, Timing and Technique of Surgery for Encapsulating Peritoneal Sclerosis
T Augustine, Manchester, UK
What is the ideal treatment for encapsulating sclerosing peritonitis?
Can surgery be life saving?

12.00-12.20 Severe and Relapsing Peritonitis
B Issad, Paris, France
Peritonitis remains a leading complication of PD and sometimes is associated with considerable morbidity. In most cases peritoneal infections are more benign and treated effectively by local specific antibiotic therapy. But in some cases peritonitis may be severe and relapsing. The infection fails to respond to medical treatment and surgical exploration occasionally reveals severe lesions. The purpose of this presentation is to discuss about the assessment of patients who fail to demonstrate clinical improvement and how to manage episodes of peritonitis caused by more aggressive micro-organisms (eg- s aureus, enteric g negative, Fungal peritonitis) prognosis, removal catheter and we focus on prevention relapses, because they are harmful for the long term preservation of the peritoneal depurative capacities.

12.20-13.00 Diagnosis and Treatment of Coronary Artery Disease in CKD stage 5: Can We Do Better?
A De Vriese, Bruges, Belgium
More than 50% of our patients die from cardiovascular causes, most of them because of coronary disease. Nevertheless, it is clear that cardiovascular disease is undertreated and underdiagnosed in CKD/RRT patients. How should we diagnose coronary disease, how should we treat (medication, PCI with our without stent, CABG) and what is the outcome. Place of aspirin, statins, beta blocking agents. Should also include pre-TX cardiac investigations.

Erasme Hall

13.00–14.00

Lunch/Posters/Exhibition
(Lunch can be taken into the auditorium for the Gambro symposium)

Exhibition Foyer

13.15-14.45

Industry Symposium IV 

Dialysis Opinion Symposium on Innovations in PD
Chair: S Davies, Stoke-on-Trent, United Kingdom; I Ledebo, Lund, Sweden

Why Dialysis Opinions?
S Davies

Why PD in incident patients?
J Heaf

Innovations in PD fluid physiology
J Heaf

Most urgent clinical complication in PD
W van Biesen

Priority issues in cycler-operated PD
W van Biesen

Innovations for improved outcome and quality of life 
S Davies

Survey results from ISPD 2008
I Ledebo

Erasme Hall

13.00-14.15

Poster Session II

A selection of the best posters will be discussed in a walking tour of the poster area and will be lead by:

Clinical PD - Posters: P38-P73
T Ulinski, France ; J Chanliau, France; M Dratwa, Belgium

Dialysis Solutions - Posters : P74-P90
R Krediet, The Netherlands; B Faller, France

Infection - Posters: P91-P105
F Schaefer, Germany; E Boulanger, France

Biology Membrane & Function - Posters: P106-P108, P110-P123 & P146
B Rippe, Sweden & D Uelingher, Switzerland

Ground Floor

14.45–15.45

Mini Symposium 2

Gastro-Intestinal and Feeding Problems in PD Patients
Chairs: PY Durand, Quimper, France; G. Gahl, Berlin, Germany

There is a poor appreciation of the symptoms of advanced CKD. This session will look at the evidence base for the prevalence of uremic symptoms, how they should be measured and identified and consider non-dialysis methods for their control.

14.45-15.15 Understanding the Symptoms of Patients
with Advanced CKD
F Murtagh, London, UK

15.15-15.45 Upper Gastro-Intestinal Symptoms in PD: What, Why and How to Treat?
B Bammens, Leuven, Belgium
Delayed gastric emptying can cause reflux, and nausea, and poor appetite in PD patients. What are the underlying pathphsyiological mechanisms, and how can we avoid/treat the problem.

Salle Schuman

14.45-15.45

Mini Symposium 3

Modelling the Membrane Without Equations Revisited:
The Role of The Interstitium  
Moderator: S Davies, Stoke on Trent, UK

Interactive Debate Featuring
B Rippe, Lund, Sweden and S Davies, Stoke on Trent, UK
What is the most optimal way to test and describe the peritoneal membrane in relation to transport of solutes. Should we use different tests for different situations, e.g. diagnostic vs prescription management? What is the place of available software? What is the role of the interstitium, and how do we integrate this in the existing membrane evaluation tests? This will be a practical session using interactive demonstrations to illustrate points. 

Erasme Hall

15.45-16.15

Tea/Coffee

Exhibition Forum

16.15-18.15

Clinical Practice Session III

PD Adequacy: Beyond Small Solute Clearance  
Chair: C Verger, Pontoise, France

Sodium removal is of importance to maintain fluid balance in PD patients.  How can we increase (peritoneal) solute removal in PD? Use of low sodium solutions, use of icodextrin, but also avoidance of sodium sieving should be discussed. Special focus will be given also on the measurement of sodium dialysate.

16.15-16.45 Holistic View on Adequate PD
W Van Biesen, Gent, Belgium
PD adequacy is far more than just obtaining ‘small solute clearance’. Many other factors, such as volume control, nutrition, anaemia are of importance. Also avoidance of toxicity should be taken into account.

16.45-17.15 Which Solutes should we Target and is their Removal Different in PD vs HD
R Vanholder, Gent, Belgium
When talking about “adequacy” solute removal is one of the major  topics. It is however not quite clear which uremic toxins we should remove. It is also clear that different molecules have a different kinetic behaviour. How can PD and HD be compared in terms of solute removal patterns? Are there measures that can be used consistently both in PD and HD?

17.15-17.35 Sodium Removal in PD Patients
P Freida, Cherbourg, France

17.35-17.55 Kinetic Modelling in PD: The Way to Improve Prescription?
D Uehlinger, Bern, Switzerland
Understanding the peritoneal transport physiology is not easy, and translating it into an adequate prescription is sometimes cumbersome, as many conflictive mechanisms play a role. Can computer software (kinetic modelling) be of help in the prescription, and how, and what are the potential pitfalls?

17.55-18.15 How to Evaluate and Improve Nutritional Status
D Fouque, Lyon, France
Nutritional status is an important marker of adequacy. Which investigations should we use to evaluate nutritional status of our patients, and what can we do to improve it? Dietary instructions, special feeding/food? Anabolic agents? Differences between HD-PD? Practical recommendations!!

Erasme Hall

16.15-18.15

Free Communications II

Ultrafiltration, Membrane Biology Including Sclerosis, Solutions
Chairs: J D Williams, Cardiff, UK; F Schaefer,Heidelberg, Germany

16.15-16.27 O-6 Indices of Cardiac Dysfunction in Peritoneal Dialysis Patients are Associated with Relative Increases in Intravascular Volume Rather than Extracellular Water Relative to Total Body Water
Kay Tan, Biju John, Frauke Wenzelburger, Yu Ting Tan, Eveline Lee,
John E Sanderson, Simon J Davies

16.27-16.39 O-7 Nutritional Assessment using Body Composition Monitoring in Peritoneal Dialysis Patients. Variables Determining Body Mass, Fat Tissue and Lean Tissue Index
Adrian Covic, Wim van Biesen, Stanley Fan, Kathleen Claes, Monika Lichodziejewska-Niemierko, Christian Verger, Jürg Steiger, Volker Schoder, Adelheid Gauly, Rainer Himmele

16.39-16.51 O-8 Twenty-Four-Hour Ultrafiltration Efficiency of Combined Glucose and Icodextrin Peritoneal Dialysis (Pd) Solutions
Alp Akonur, John K. Leypoldt

16.51-17.03 O-9 The Extracellular Water Corrected for Height Predicts Technique Survival in Peritoneal Dialysis Patients
Meltem Sezis Demirci, Cenk Demirci, Hamad Dheir, Erhan Tatar, Ozkan Gungor, Mumtaz Yilmaz, Gulay Asci, Ali Basci, Ercan Ok, Mehmet Ozkahya

17.03-17.15 O-10 Longitudinal Analysis of Solute and Fluid Transport in Peritoneal Dialysis Patients: The Conventional Versus a More Biocompatible Pd Solution
Annemieke Coester, Watske Smit, Dirk Struijk, Raymond Krediet

17.15-17.27 O-11 Free Water Transport in Children on Peritoneal dialysis Varies with Different Types of Dialysis Solution and with Time on Peritoneal Dialysis
Renske Raaijmakers, Watske Smit, Annemieke Coester, Raymond Krediet, Cornelis Schroder

17.27-17.39 O-12 Encapsulating Peritoneal Sclerosis in Patients on Peritoneal Dialysis: A Single-Center  Experience
Valerio Vizzardi, Massimo Sandrini, Luigi Manili, Giuseppe Mazzola,
Francesca Valerio, Laura Econimo, Giuliano Brunori, Giovanni C Cancarini

17.39-17.51 O-13 Development of a Uremic Peritoneal Infusion Rat Model for Encapsulating Peritoneal Sclerosis
Anniek Vlijm, Denise E. Sampimon, Marijke de Graaff, Dirk G. Struijk,
Raymond T. Krediet

17.51-18.03 O-14 Characterization of Peritoneal Alternatively
Activated Macrophages (aam): Implications for a Role in Peritoneal Membrane Fibrosis
Rafael Selgas, Teresa Bellon, Virginia Martinez, Baltasar Lucendo,
Gloria Del Peso, Maria Jose Castro, Luiz Aroeira, Rafael Sanchez-Villanueva, Auxiliadora Bajo

18.03-18.15 O-15 Reduced Residual Renal Function is Associated with Endothelial Dysfunction in Patients Undergoing Peritoneal Dialysis
Seung Hyeok Han, Ea Wha Kang, Hyang Sook Yoon, Shin-Wook Kang,
Dae Suk Han

Tivoli II

16.15-17.45

Mini Symposium 4

PD and Transplantation
Chairs: P Harden, Oxford, UK; J P Ryckelynck, Caen, France

16.15-16.45 Impact of Pre-transplant Modality on Outcome
JP Ryckelynck, Caen, France
Impact of pre-TX strategies on outcome; should include PD vs HD, but also probability for TX, EPS after TX?

16.45-17.15 PD in the Failed Transplant Patient
V Jassal, Toronto, Canada
Immunosuppression in PD patients, transport status, outcome, outcome PD vs HD, prophylaxis.

17.15-17.45 Impact of CKD Stage 4/5 in the Failing Transplant:
The Forgotten Cohort?
P Harden, Oxford, UK
The failing transplant patient is often neglected in the pre-ESRD care.
There can be an important role for good CKD stage 4 care in this patient
group however.

Salle Schuman

18.30

Limited Coaches Depart for St Paul Church (optional concert)

19.00-20.00

Concert in St Paul Church provided free by the City of Strasbourg
- Société des Cors de Chasse de Strasbourg-Neudorf
Chorale Cantalia
Daniel Maurer - Organiste

07.30-12.45
07.30-12.45
09.00-11.30

Registration and Posters Open
Speaker Presentation Check-In
Exhibition & Internet Cafe Open

Entrance Erasme
Salon President
Exhibition Foyer

Masterclasses A3/B3/C3
(by invitation only)

07.45-08.30 Theme A3: Clinical Epidemiology and Clinical Design
D Evans, Paris, France  

07.45-08.30 Theme B3: Pre-Dialysis, Education & Preparation
Wim Van Biesen, Gent, Belgium

07.45-08.30 Theme C3: Peritoneal Morphology
O DeVuyst, Brussels, Belgium

Kleber

Gutenberg

Rohan

09.00–11.00

Symposium IV

Basic Science Fibrosis or Inflammation?
Chair: D Johnson, Brisbane, Australia; E Boulanger, Lille, France

09.00-09.20 ET’s and PETS: Animal Models for PD in Europe
P Terwee, Amsterdam, The Netherlands
Where do we stand with animal models in Europe? Can animal models really increase our understanding of the peritoneal membrane, and how far are can these data be translated to human physiology? Pitfalls of animal models in PD.

09.20-09.45 Genetically Modified Mice: Inborn Messages for PD?
O Devuyst, Brussels, Belgium
Can genetically modified (knock out) animals (mice) have a role in PD research?

09.45-10.10 Inflammation is Not Only a Marker But Also Plays a Causative Role in Clinical Putcomes
O Heimburger, Stockholm, Sweden
This talk should give an overview on how inflammation is the common pathway both in deterioration of the peritoneal membrane, as for the cardiovascular and malnutrition outcome of patients with ESRD. What can we do to avoid/block the effects of inflammation in our patients? How to measure inflammatory status in our patients?  

10.10-10.35 Our Current Understanding of Peritoneal Damage During PD: Fibrosis is the Key
J Witowski, Poznan, Poland
There is evidence that a lot of damage of the peritoneal membrane is not related to inflammation, but rather to (in)direct stimulation of fibrosis by pathways other than inflammation, eg, TGF beta  

10.35-11.00 Chameleon Cells: Epithelial to Mesenchymal Transition
R Selgas, Madrid, Spain
The transition of cells from one cell type to another is a fascinating process. What are the relevant messages from our current understanding of these processes to PD. Can eventually be extended also to the transition to osteoblastic cells of vascular smooth muscle cells. Focus should thus be on the molecular and cellular mechanisms behind the observed EMT, rather than on the observations themselves.

Erasme hall

09.00–11.00

Symposium V

PD from a Broader View:
What the Different French Nephrology Societies can Contribute to PD
Chairs: J Chanliau, Nancy, France; JP Ryckelynck, Caen, France

This session should allow the different societies that constitute the local organising committee to express their view on how they can contribute to “home dialysis” and/or PD.

09.00-09.30 Muscle Mass in PD Patients
C Verger, Pontoise, France  

09.30-10.00 Dry Weight Assessment in PD
F Vrtovsnik, Paris, France  

10.00-10.30 Optimal APD Prescription
PY Durand, Quimper, France    

10.30-11.00 Cardio Vascular Risks in Children in ESRF
T Ulinski, Paris, France

Salle Schuman

11.00-11.30

Tea/Coffee (Exhibition, Internet Café & Posters close at 11.30)

Exhibition Foyer

11.30-12.30

Free Communications III

Basic Science and Infection
Chairs: A Ekstrand, Helsinki, Finland; M Dratwa, Brussels, Belgium

11.30-11.42 O-16 Effects of BicaVera® Dialysate for Peritoneal Dialysis
on the Epithelial-to-Mesenchymal Transition (EMT) of the Mesothelial Cell (MC)
Jose Antonio Sanchez-Tomero, Antonio Fernandez-Perpen,
Maria Auxiladora Bajo, Maria Luisa Perez-Lozano, Gloria Del Peso, Pedro Albar, Abelardo Aguilera, Antonio Cirugeda, Manuel Lopez-Cabrera, Rafael Selgas

11.42-11.54 O-17 Functional Relevance of Vegf (Vascular Endothelial Growth Factor) and Vegf Receptors (Vegfrs) Switch During Peritoneal Dialysis-Induced Epithelial Mesenchymal Transition (Emt) of
Mesothelial Cells
Maria Luisa Perez-Lozano, Jose Antonio Jimenez-Heffernan,
Abelardo Aguilera, Pilar Sandoval, Patricia Albar, Maria Auxiliadora Bajo,
Jose Antonio Sanchez-Tomero, Rafael Selgas, Manuel Lopez-Cabrera

11.54-12.06 O-18 Relationship Between Solute Transport Status and Inflammatory Cytokines in Peritoneal Dialysis
Mark Lambie, James Chess, Kit Huckvale, Nick Topley, Simon Davies

12.06-12.18 O-19 Ultrasonographic Evaluation of Peritoneal Membrane Thickness and Comparison with the Duration and Effectiveness of Peritoneal Dialysis Gokhan Temiz, Sultan Ozkurt, Gul Mukerrem, Garip Sahin, Nevbahar Akcar Degirmenci, Ahmet Ugur Yalcin

12.18-12.30 O-20 Human γδ T Cells Drive the Acute Inflammation in Bacterial Infection: Implications for PD-Related Peritonitis
Matthias Eberl, Martin S Davey, Gareth W Roberts, Chan-Yu Lin,
James Chess, Holly Ciesielczuk, Rob Shorten, John D Williams,
Nicholas Topley, Bernhard Moser

Tivoli II

11.30-12.30

Mini Symposium V

Future Developments in PD
Chairs: R Krediet, Amsterdam, The Netherlands; J D Williams, Cardiff, UK

11.30-11.50 High flow PD: Still Viable?
A Vychytil, Wien, Austria
High flow PD has been advocated as a way to improve (small solute) clearance, but technical problems, and the understanding that small solute clearance is probably not so important after all, have decreased the impetus of research in this area. Is there still room for further development of this type of treatment?

11.50-12.10 New Peritoneal Dialysis Solutions: Which Way to Go?
S Fan, London, UK
Is there room for new PD solutions? If yes, which should be the properties of such a solution, and what are potential candidates for modification?

12.10-12.30 PD and Absorption Techniques: Brothers in Arms Towards a Wearable Artificial Kidney?
R Krediet, Amsterdam, The Netherlands
PD is the first really “wearable artificial kidney”. However, newer systems have been described using adsorption techniques, so that the dialysate can be recycled. Is this a future way to go?

Erasme Hall

11.30-12.30

Mini Symposium VI

Transition from Paediatric to Adult Nephrology
Chairs: M Tsimaratos, Marseille, France; P Harden, Oxford, UK

11.30-11.50 What the Adult Nephrologist Should Know About Congenital Nephrological Disease
M Tsimaratos, Marseille, France
Due to better survival, youngsters with “strange congenital disease” will come up to the adult nephrology clinic. What does the adult nephrologist need to know to take care of these teenagers?

11.50-12.10 Intensive and Daily Dialysis
M Fischbach, Strasbourg, France
Results of the experience in Strasbourg with intensive HD and the impact on treatment approach in children; how to plan treatment in the long run; Is as soon as possible TX always the best option?

12.10-12.30 Transition and its Problems
P Harden, Oxford, UK
The transition from the protected paediatric ward to the hostile environment of adult nephrology care takes place during the turmoil of puberty and identity problems. This causes a lot of problems, with a strong negative impact on outcomes.

Salle Schuman

12.30-12.45

Prizes & Closing Remarks
Chairs: J D Williams, Cardiff, UK; M Fischbach, Strasbourg, France

Erasme Hall